These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16584439)

  • 1. Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience.
    Schinzel H; Berghoff K; Beuermann I; Sauer O; von Mach MA; Weilemann LS
    Transfusion; 2006 Apr; 46(4):624-9. PubMed ID: 16584439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin.
    ten Berg MJ; van den Bemt PM; Huisman A; Schobben AF; Egberts TC; van Solinge WW
    Ann Pharmacother; 2009 Sep; 43(9):1405-12. PubMed ID: 19690229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation with low-molecular-weight heparin in patients with heart diseases.
    Bechtold H; Janssen D
    Eur J Med Res; 2004 Apr; 9(4):186-98. PubMed ID: 15210399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
    Barbour LA; Oja JL; Schultz LK
    Am J Obstet Gynecol; 2004 Sep; 191(3):1024-9. PubMed ID: 15467584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
    Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
    Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing.
    Näsström B; Stegmayr B; Gupta J; Olivecrona G; Olivecrona T
    Nephrol Dial Transplant; 2005 Jun; 20(6):1172-9. PubMed ID: 15797889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL; Bungard TJ
    Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous hemothorax following anticoagulation with low-molecular-weight heparin.
    Ganguli A; Walker L; FitzGerald RJ; Pirmohamed M
    Ann Pharmacother; 2009 Sep; 43(9):1528-31. PubMed ID: 19690222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the low molecular weight heparin dalteparin in cats.
    Mischke R; Schmitt J; Wolken S; Böhm C; Wolf P; Kietzmann M
    Vet J; 2012 Jun; 192(3):299-303. PubMed ID: 21978598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
    Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
    J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complications of double-filtration plasmapheresis.
    Yeh JH; Chen WH; Chiu HC
    Transfusion; 2004 Nov; 44(11):1621-5. PubMed ID: 15504168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin.
    Abildgaard U; Sandset PM; Hammerstrøm J; Gjestvang FT; Tveit A
    Thromb Res; 2009 Jul; 124(3):262-7. PubMed ID: 19162303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
    Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
    Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.